Mastocytosis-induced osteoporosis

G. S. Maier; D. Percic; U. Maus; A. A. Kurth

doi:10.1055/s-0038-1630109

Osteologie, Table of Contents

Osteologie 2013; 22(02): 136-139
DOI: 10.1055/s-0038-1630109

Original and review articles

Schattauer GmbH

Mastocytosis-induced osteoporosis

Rare but severeMastozytose-induzierte Osteoporose Eine seltene, aber dennoch nicht zu unterschätzende Krankheit

Authors

G. S. Maier

¹Klinik und Poliklinik für Unfallchirurgie, Universitätsklinikum Gießen, Germany

²Department of Orthopedic Surgery, Johannes-Gutenberg-University, Mainz, Germany
D. Percic

²Department of Orthopedic Surgery, Johannes-Gutenberg-University, Mainz, Germany
U. Maus

³Orthopedic center Oldenburger Münsterland, St. Antonius-Stift Emstek, Emstek, Germany
A. A. Kurth

⁴Mainz, Germany

Abstract

Summary

Background: Systemic mastocytosis is a rare disease characterised by accumulation of mast cells in at least one extracutaneous organ, including bone marrow. It is increasingly recognized as a possible cause of secondary osteoporosis. We conducted a literature review on the role of mast cells in osteoporosis including data/peer reviewed articles/ journals from 1957 to 2012. Our aim was to evaluate the current state of research and to offer an overview of current therapeutic options/measures/treatments.

Methods: A retrospective review of peer r eviewed/published literature was performed using MEDLINE databases from 1957 to 2012. The keywords “osteoporosis” and “mast cells/mastocytosis” revealed 201 articles, limi ted to English and German articles. The following criteria were included: studies on, or case studies of either mastocytosis induced osteoporosis, or the role of mast cells in osteoporosis or the relation of bone remodeling and mastocytosis.

Results/Conclusion: Mast cells seem to play an important role in bone turnover. Their byproducts are responsible for increased bone resorption. However, the skeletal involvement is mainly situated in trabecular bone, which determines vertebral collapse. This review increases the awareness that patients with systemic mastocytosis would benefit from diagnostic workup with regard to bone health, as this rather rare cause of secondary osteoporosis can lead to significantly high rates of mortality.

Zusammenfassung

Hintergrund: Die systemische Mastozytose ist eine seltene Erkrankung, die durch die abnorme Mastzellproliferation in wenigstens einem extrakutanem Gewebe, unter anderem auch im Knochenmark, charakterisiert wird. Die Rolle der Mastzellen und ihrer Mediatoren als potenzielle Ursachen sekundärer Osteoporose wird zunehmend diskutiert. Mit dieser Literaturübersicht der Jahre 1957 bis 2012 wollten wir sowohl den aktuellen Stand der Wissenschaft als auch mögliche Therapieoptionen wiedergeben.

Material und Methoden: Wir führten eine retrospektive Analyse der Literatur von 1957 bis 2012 mit Hilfe der MEDLINE-Datenbank durch. Die Suchbegriffe “osteoporosis” und “mast cells” bzw. “mastocytosis” ergaben 201 Treffer in englischer oder deutscher Sprache. Wir berücksichtigten Originalia und Fallstudien, die sich entweder mit Mastozytoseinduzierter Osteoporose oder der Bedeutung von Mastzellen bei Osteoporose auseinandersetzen.

Ergebnisse/Schlussfolgerung: Mastzellen scheinen eine gewichtige Rolle im Knochenstoffwechsel inne zu haben, Nebenprodukte der Mastzellen sind für vermehrten Knochenabbau verantwortlich. Mit dieser Literaturübersicht wollten wir daran erinnern, dass bei allen Patienten mit einer systemischen Mastozytose der Knochenstoffwechsel im Hinblick auf eine sekundäre Osteoporose untersucht werden sollte. Diese ist zwar selten, jedoch äußerst morbide.

Keywords

Mast cells - mastocytosis - osteoporosis

Schlüsselwörter

Mastzellen - Mastozytose - Osteoporose

Full Text

References

References
1 Amon U, Hartmann K, Horny HP, Nowak A. Mastocytosis – an update. J Dtsch Dermatol Ges. 2010 8. (9) 695-711 quiz 2.
2 Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology 2007; 74 (2) 121-132.
3 Soderholm JD. Mast cells and mastocytosis. Dig Dis 2009; 27 (Suppl 1) 129-136.
4 Valent P. Diagnostic evaluation and classification of mastocytosis. Immunol Allergy Clin North Am 2006; 26 (3) 515-534.
5 Rossini M, Zanotti R, Bonadonna P. et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 2011; 49 (4) 880-885.
6 Benucci M, Bettazzi C, Bracci S. et al. Systemic mastocytosis with skeletal involvement: a case report and review of the literature. Clin Cases Miner Bone Metab 2009; 6 (1) 66-70.
7 Chiappetta N, Gruber B. The role of mast cells in osteoporosis. Semin Arthritis Rheum 2006; 36 (1) 32-36.
8 Barete S, Assous N, de Gennes C. et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010; 69 (10) 1838-1841.
9 Brumsen C, Hamdy NA, Papapoulos SE. Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 2002; 17 (4) 567-569.
10 Castells MC, Friend DS, Bunnell CA, Hu X, Kraus M, Osteen RT, et al. The presence of membrane-bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis. J Allergy Clin Immunol 1996; 98 (4) 831-840.
11 Tharp MD, Chan IJ. Mastocytosis. Adv Dermatol 2003; 19: 207-236.
12 Fallon MD, Whyte MP, Teitelbaum SL. Systemic mastocytosis associated with generalized osteopenia. Histopathological characterization of the skeletal lesion using undecalcified bone from two patients. Hum Pathol 1981; 12 (9) 813-820.
13 Gay S, Jones Jr. RE, Huang GQ, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989; 92 (2) 301-303.
14 Silberstein R, Melnick M, Greenberg G, Minkin C. Bone remodeling in W/Wv mast cell deficient mice. Bone 1991; 12 (4) 227-236.
15 Suzuki K, Lees M, Newlands GF. et al. Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II. Biochem J 1995; 305 (Pt 1) 301-306.
16 Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2002; 128 (4) 344-350.
17 Fitzpatrick LA, Buzas E, Gagne TJ. et al. Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss. Proc Natl Acad Sci U S A 2003; 100 (10) 6027-6032.
18 Blair HC, Dong SS, Julian BA. Expression of stem cell factor by osteoblasts in normal and hyperparathyroid bone: relation to ectopic mast cell differentiation. Virchows Arch 1999; 435 (1) 50-57.
19 Lotinun S, Sibonga JD, Turner RT. Triazolopyrimidine (trapidil), a platelet-derived growth factor antagonist, inhibits parathyroid bone disease in an animal model for chronic hyperparathyroidism. Endocrinology 2003; 144 (5) 2000-2007.
20 Levi-Schaffer F, Bar Shavit. Osteoblast-like cell line maintains in vitro rat peritoneal mast cell viability and functional activity. Immunology 1990; 69 (1) 145-149.
21 Chines A, Pacifici R, Avioli LA. et al. Systemic mastocytosis and osteoporosis. Osteoporos Int 1993; 3 (Suppl 1) 147-149.
22 Andrew SM, Freemont AJ. Skeletal mastocytosis. J Clin Pathol 1993; 46 (11) 1033-1035.
23 Laroche M, Livideanu C, Paul C, Cantagrel A. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 2011; 124 (8) 776-778.
24 Donker ML, Bakker NA, Jaspers WJ, Verhage AH. Two patients with osteoporosis: initial presentation of systemic mastocytosis. J Bone Miner Metab 2008; 26 (2) 199-202.
25 Kruger A, Hamann C, Brendel C. et al. Multimodal therapy for vertebral involvement of systemic mastocytosis. Spine (Phila Pa 1976) 2009; 34 (17) E626-E628.
26 van der Veer E, van der Goot W, de Monchy JG. et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012; 67 (3) 431-438.
27 Johansson C, Roupe G, Lindstedt G, Mellstrom D. Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 1996; 25 (1) 1-7.
28 Delling G, Ritzel H, Werner M. Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases. Pathologe 2001; 22 (2) 132-140.
29 Travis WD, Li CY, Bergstralh EJ. et al. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 1988; 67 (6) 345-368.
30 Marshall A, Kavanagh RT, Crisp AJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 1997; 36 (3) 393-396.
31 Graves 3rd L, Stechschulte DJ, Morris DC, Lukert BP. Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. J Bone Miner Res 1990; 5 (11) 1113-1119.
32 Lim KH, Pardanani A, Butterfield JH. et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009; 84 (12) 790-794.
33 Laroche M, Bret J, Brouchet A, Mazieres B. Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis. Clin Rheumatol 2007; 26 (2) 242-243.
34 Lehmann T, Beyeler C, Lammle B. et al. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol 1996; 35 (9) 898-900.
35 Grieser T, Minne HW. Systemic mastocytosis and skeletal lesions. Lancet 1997; 350 (9084) 1103-1104.
36 Guillaume N, Desoutter J, Chandesris O. et al. Bone complications of mastocytosis: A link between clinical and biological characteristics. Am J Med. 2012 Nov 28 [Epub ahead of print].